NCT05467761View on ClinicalTrials.gov

Bioavailability Study of Psilocybin in Normal Adults

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

June 30, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions

Healthy

Interventions

DRUG

Oral Psilocybin

25mg orally

DRUG

IV Psilocybin

5mg intravenously

Trial Locations (1)

53705

University of Wisconsin, Madison

Sponsors

Collaborators (1)

TRYP Therapeutics

All Listed Sponsors

collaborator

TRYP Therapeutics

INDUSTRY

lead

University of Wisconsin, Madison

OTHER

NCT05467761 - Bioavailability Study of Psilocybin in Normal Adults | Biotech Hunter | Biotech Hunter